These data suggest that in tumor cells, the ability of the IDH1 or IDH2 mutant to produce D-2-HG far outpaces the ability of D-2-HGDH to consume D-2-HG, leading to the accumulation of D-2-HG and subsequently the formation and progression of gliomas. The gene discussed is IDH1; the disease is central nervous system cancer.